Ï B. åîïìïëïãåßôáé...

Boy Ãåéá óáò.

ÏíïìÜæïìáé Â.

¾óôåñá áðü ôçí êáôÜèåóç áßôçóçò êáé ôéò áðáéôïýìåíåò õãåéïíïìéêÝò åîåôÜóåéò êáé áèëçôéêÝò äïêéìáóßåò, ðÝñáóá óôï Ìç÷áíéêü Óþìá óôñáôïý îçñÜò ùò åðáããåëìáôßáò ïðëßôçò.

Óôç óõíÝ÷åéá, ðáñïõóéÜóôçêá óôï Íáýðëéï, óôï ËïõôñÜêé êáé óôçí ÐÜôñá üðïõ êáé Ýêáíá ôç óôñáôéùôéêÞ åêðáßäåõóÞ ìïõ êáé ìåôáôÝèçêá ìüíéìá óôçí ðüëç ðïõ æù ôþñá.

Äýï ìå ôñåéò ìÞíåò ðñéí áðü ôá ×ñéóôïýãåííá, Ýñ÷åôáé äéáôáãÞ üôé ðñÝðåé íá ðáñïõóéáóôþ óôï Ðïëýêáóôñï ãéá âáóéêÞ åêðáßäåõóç ðñïêåéìÝíïõ íá ðÜù óå óôñáôéùôéêÞ áðïóôïëÞ óôï åîùôåñéêü.
ÐáñÜëëçëá ìå ôçí åêðáßäåõóÞ ìïõ, Ýðñåðå íá åéóá÷èþ óôï óôñáôéùôéêü íïóïêïìåßï ãéá ôéò åîïíõ÷éóôéêÝò åîåôÜóåéò ðïõ åßíáé õðï÷ñåùôéêÝò ãéá üëïõò ôïõò åðáããåëìáôßåò ïðëßôåò ðïõ åðéëÝ÷ôçêáí ãéá íá ðÜíå óôï åîùôåñéêü.
¸ôóé ëïéðüí êáé Ýãéíå.

Óôï óôñáôéùôéêü íïóïêïìåßï äéáðéóôþèçêå êáé ìïõ áíáêïéíþèçêå ãéá ðñþôç öïñÜ üôé ðÜó÷ù áðü ôï Óýíäñïìï ôçò Åðßêôçôçò ÁíïóïëïãéêÞò ÁíåðÜñêåéáò ôïõ áíèñþðïõ (HIV ëïßìùîç) ýóôåñá áðü ôçí áíÜëõóç ðïëëþí äåéãìÜôùí áßìáôïò ðïõ ðñïóêïìßóôçêáí óôï íïóïêïìåßï.
×ùñßò íá Ý÷ù óõíåéäçôïðïéÞóåé áðüëõôá ôé ìïõ åß÷å óõìâåß êáé Ý÷ïíôáò ìáæÝøåé ôéò áðåéñïåëÜ÷éóôåò äõíÜìåéò ðïõ ìïõ åß÷áí áðïìåßíåé, ãíùóôïðïéþ ôá ãåãïíüôá áìÝóùò óôïõò ãïíåßò ìïõ êáé óôá áäÝñöéá ìïõ.
ÐáñÝìåéíá íïóçëåõüìåíïò óôï íïóïêïìåßï ãéá áñêåôÝò çìÝñåò, ðñïêåéìÝíïõ íá óéãïõñåõôïýí ïé ãéáôñïß ãéá ôçí áóèÝíåéÜ ìïõ.
¹ìïõí ôüóï óõíôåôñéììÝíïò, ðïõ ðñïóðáèïýóá íá ìáæÝøù ôá êïììÜôéá ìïõ, ôéò äõíÜìåéò ìïõ, ðñïêåéìÝíïõ íá ôï ðù áìÝóùò óôç ãõíáßêá ìïõ, ãéá íá äïýìå áðü êïéíïý ôé èá êÜíïõìå.
ÁëëÜ ðÜíù áð’ üëá ãéá íá êÜíïõí ôçí áíôßóôïé÷ç åîÝôáóç êáé óôç ãõíáßêá ìïõ êáé óôï ðáéäß ìïõ, ãéá íá äéáðéóôþóïõìå üôé óßãïõñá äåí ðÜó÷ïõí áðü ôïí éü.
ÁõôÞ Þôáí ç ìüíç Ýãíïéá ìïõ, ç ìüíç áãùíßá ìïõ.
Ï åáõôüò ìïõ åß÷å ìðåé óôçí Üêñç.
Äå ìå Ýíïéáæå ôßðïôá, ðáñÜ ìüíï ç õãåßá ôçò ãõíáßêáò ìïõ êáé ôïõ ðáéäéïý ìïõ.

ÁíÝêôçóá ëïéðüí ôéò äõíÜìåéò ìïõ êáé ôï øõ÷éêü ìïõ óèÝíïò êáé Ý÷ïíôáò óõìðáñáóôÜôåò ôïõò ãïíåßò ìïõ, ôá áäÝñöéá ìïõ êáé ôïí êáëýôåñü ìïõ ößëï, ðáßñíù ôç äýíáìç êáé ôï áíáêïéíþíù óôç ãõíáßêá ìïõ áíÞìåñá ôçò Ðñùôï÷ñïíéÜò.
Áðü ôç óôéãìÞ ðïõ ôï Ýìáèá ìÝ÷ñé ôç óôéãìÞ ðïõ ôï áíáêïßíùóá óôç ãõíáßêá ìïõ, äåí Þñèáìå óå åñùôéêÞ åðáöÞ, ðñïêåéìÝíïõ íá ìçí èÝóù óå êßíäõíï ôçí óùìáôéêÞ ôçò áêåñáéüôçôá êáé áðü ôçí Üëëç ôï äéÜóôçìá áõôü Þôáí ðïëý ìéêñü êé åãþ ìðáéíüâãáéíá óôï íïóïêïìåßï.

¾óôåñá áðü ôçí áíáêïßíùóç óôç ãõíáßêá ìïõ üôé åßìáé öïñÝáò ôïõ éïý HIV, áìÝóùò êÜíáìå ìáæß ôçí áíôßóôïé÷ç áéìáôïëïãéêÞ åîÝôáóç óå ìéêñïâéïëïãéêü åñãáóôÞñéï.
Åíþ ç ãõíáßêá ìïõ ìå åß÷å êáèçóõ÷Üóåé üôé äå èá ôï ðåé óå êáíÝíáí, áðü ôç óôéãìÞ ðïõ ôá áðïôåëÝóìáôá âãÞêáí áñíçôéêÜ êáé äåí Ýðáó÷å ïýôå áõôÞ ïýôå ôï ðáéäß ìáò áðü ôïí éü, ôçí áìÝóùò åðüìåíç çìÝñá áíáêïßíùóå óôïõò ãïíåßò ôçò üôé åßìáé ïñïèåôéêüò.
Ç Üìåóç áíôßäñáóÞ ôïõò Þôáí íá ìå äéþîïõí áðü ôï óðßôé ôïõò êáé íá ìïõ áðáãïñåýóïõí íá âëÝðù ôï ðáéäß ìïõ.

Åãþ åðÝóôñåøá óôçí õðçñåóßá ìïõ ãéá íá ôáêôïðïéÞóù ôá èÝìáôá ìå ôç äïõëåéÜ ìïõ.
Ëüãù ôçò êáôÜóôáóÞò ìïõ äå ìå Ýêáíáí ðëÝïí äåêôü óôï óôñáôü êáé ìïõ Ýäùóáí ÷áñôß áðüëõóçò ìå É4 ðáèïëïãéêü.

¸÷ïíôáò ÷Üóåé êáé ôç äïõëåéÜ ìïõ, ôéò áìÝóùò åðüìåíåò çìÝñåò ðáñïõóßá ôïõ ðáôÝñá ìïõ Þñèáí êÜðïéïé óôï óðßôé ìïõ åê ìÝñïõò ôçò ãõíáßêáò ìïõ êáé ðÞñáí áðü ìÝóá ó÷åäüí üëá ôá Ýðéðëá êáé ôá áíôéêåßìåíá ðïõ õðÞñ÷áí.
Åãþ ÷ùñßò íá öÝñù êáìßá áíôßóôáóç êáé ìå ôçí åíôýðùóç üôé ôá ÷ñåéáæüôáí (åíþ ôþñá ôá Ý÷åé ôïðïèåôÞóåé óå áðïèçêåõôéêü ÷þñï) ôçò åðÝôñåøá íá ðÜñåé üôé Þèåëå. ÐÞñå ó÷åäüí ôá ðÜíôá åêôüò áðü ôá äþñá, ôá ñïý÷á êáé ôá êïóìÞìáôá ðïõ åß÷áí áãïñÜóåé ïé ãïíåßò ìïõ êáé ôá áäÝñöéá ìïõ ó’ áõôÞí êáé ôï ðáéäß ìáò, ôá ïðïßá âñßóêïíôáé óôï óðßôé ìïõ Üèéêôá êáé á÷ñçóéìïðïßçôá.

Ðáñüëï áõôÜ üìùò äåí Ý÷áóá êáé ðÜëé ôç äýíáìÞ ìïõ, äéüôé Ý÷ù áíèñþðïõò êïíôÜ ìïõ ðïõ ìå óôçñßæïõí.
Ïé ãïíåßò ìïõ êáé ôá áäÝñöéá ìïõ, ìïõ Ýäùóáí üëá ôá áðáñáßôçôá ÷ñÞìáôá ðáßñíïíôáò äÜíåéï ãéá íá áãïñÜóù Ýðéðëá êáé óêåýç, Ýôóé þóôå íá êÜíù êáé ðÜëé ôï óðßôé ìïõ âéþóéìï.
Áêüìç êé áí ç ãõíáßêá ìïõ åðéäéþêåé ôçí áðïìÜêñõíóÞ ìïõ áðü ôï ðáéäß ìïõ, áñíïýìåíç êÜèå öïñÜ íá ìå åíçìåñþíåé ãéá ôçí õãåßá ôïõ êáé ôçí óùìáôéêÞ ôïõ áêåñáéüôçôá, åãþ ðïôÝ äåí Ýðáøá íá åðéóêÝðôïìáé ôï ðáéäß ìïõ, íá ôïõ êÜíù äþñá ãéáôß áõôü ìå ðñïóôÜæåé ç êáñäéÜ ìïõ êáé ç ëá÷ôÜñá ìïõ íá ôï äù, áíåîÜñôçôá åÜí áíôéìåôùðßæù äýóêïëåò êáôáóôÜóåéò êáé ëåêôéêÝò åðéèÝóåéò áðü ôç ìåñéÜ ôç äéêÞ ôçò êáé ôçò ïéêïãÝíåéÜò ôçò. Êáíåßò äåí Ý÷åé ôï äéêáßùìá íá ìïõ óôåñÞóåé ôï ìïíáäéêü ðëÜóìá ôï ïðïßï áðïôåëåß ôï ëüãï ýðáñîÞò ìïõ êáé ìïõ äßíåé ôï ïîõãüíï ãéá íá æÞóù.

Ôþñá ðéá åßìáé êáé áéóèÜíïìáé ìéá ÷áñÜ, ìå êïõñÜñåé ï ãéáôñüò ìïõ ï ïðïßïò ìïõ äßíåé êáé ôçí êáôÜëëçëç áãùãÞ öáñìÜêùí.
Ôï ãåãïíüò üôé ç ãõíáßêá ìïõ äåí Þôáí ðïôÝ êïíôÜ ìïõ êáé Ýöõãå ïëïêëçñùôéêÜ áðü ôç óôéãìÞ ðïõ Ýìáèå üôé åßìáé öïñÝáò ôïõ éïý HIV, ÷ùñßò ïýôå Ýíá ëåðôü íá ðñïóðáèÞóåé íá ìåßíåé ìáæß ìïõ, ôï ìåôáöñÜæù ùò Ýëëåéøç áãÜðçò.

ÁëëÜ ôï ãåãïíüò üôé äå ìïõ åðéôñÝðåé íá ðáßñíù ôï ãéï ìïõ íá ôïí ðçãáßíù ìéá âüëôá Þ íá ôïí âëÝðù ÷ùñßò ôçí ðáñïõóßá ôñßôïõ, ôï ìåôáöñÜæù ùò áðáíèñùðéÜ áðü ôç óôéãìÞ ðïõ óôåñåß áðü ôï ðáéäß ìáò ôïí ðáôÝñá ôïõ.

B.




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò